Drug intelligence / Profile preview

Myxodin

Development stage
Unknown
Lead developer
Laboratoires Holistica
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Myxodin (also spelled Mixodin) is a natural, bioactive dietary supplement formulated to reduce joint pain and inflammation, protect cells from oxidative stress, and support liver health. Developed by Arian Salamat Sina under license from Holistica (France), Myxodin is a synergistic combination of three plant-derived active ingredients: curcumin (from turmeric, *Curcuma longa*), gingerol (from ginger, *Zingiber officinale*), and piperine (from black pepper, *Piper nigrum*). Curcumin and gingerol act as potent anti-inflammatory and antioxidant agents by inhibiting inflammatory pathways such as NF-kB and cyclooxygenase-2 (COX-2). Piperine acts as a bioenhancer, significantly increasing the oral bioavailability of curcumin by inhibiting hepatic and intestinal glucuronidation. Myxodin is commonly used as a supportive therapy for osteoarthritis, joint stiffness, and non-alcoholic fatty liver disease (NAFLD).

Brand names
MixodinMyxodin
Other names
Holistica MixodinHolistica MyxodinMixodin HolisticaMyxodin Holistica
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ALOX5 (Arachidonate 5-lipoxygenase)ABCB1 (P-glycoprotein)UGT (UDP-glucuronosyltransferase family)

Beyond the preview

Go deeper on Myxodin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myxodin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call